Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-06-23
1998-06-30
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A61K 31495
Patent
active
057734402
ABSTRACT:
A method of treating a mammal is disclosed comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## , and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms wherein said desired therapeutic effect is a reduction of at least one effect of an inflammatory disorder.
REFERENCES:
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 4188393 (1980-02-01), Neuman
patent: 4656291 (1987-04-01), Maryanoff et al.
patent: 5021416 (1991-06-01), Gluchowski
patent: 5034406 (1991-07-01), Gluchowski
patent: 5077292 (1991-12-01), Gluchowski
patent: 5112822 (1992-05-01), Gulchowski
patent: 5130441 (1992-07-01), Gluchowski
patent: 5198442 (1993-03-01), Gluchowski
patent: 5204347 (1993-04-01), Gluchowski
patent: 5231096 (1993-07-01), Gluchowski
patent: 5237072 (1993-08-01), Gluchowski
Contiello et al, J. Biol. Chem., 264 (27), pp. 16000-16007, 1989.
Thaina et al., J. Auton Pharmacol, vol. 3, No. 2, pp. 115-126, Apr. 1993.
Gellai et al, J. Pharmacol & Exp. Therapeutics, 240/3, pp. 723-728, 1987.
Gellai et al, Am. Physio. Soc., Mechanism of Alpha-2-Adrenoceptor Agonist induced Diuresis, F317-323, Am. Physio. Soc., 1988.
Chemical Abstracts CA105:481u, vol. 105, 1986.
Berridge et al, J. Pharmac., 88(2), 345-354, 1986.
Thaina et al, J. Autonomic Pharmacology, 13(2), 95-176, 1993.
Hayes et al, Neuropharmacology, 25(4), 391-396, 1986.
BR J Phamacology (England) , Jun. 1986, v. 88, No. 2 pp. 345-354, Berridge TL et al, "Characterization of alpha-adrenoceptors in the vasculature of the canine nasal mucosa".
C. F. Colpaert, CA 105:481u. 1986.
Hildebrand, J. Pharmacol Exp. Ther., 263(2) pp. 510-519, Nov. 1992 (Abstract).
Williams et al., J. Auton. Pharmacol., 10 (4):247, Aug. 1990 (Abstract).
Fondacaro et al., Am. Soc. for Pharm. , v. 247, 1987, 481-486.
Scrip Product Information, Scrip No. 1466, p. 28, Nov. 1989.
Chemical Abstracts, vol. 98, 98:921X, 1983.
Chemical Abstracts, 91:168403M, 1979.
Walland, Chemical Abstracts, vol. 88, No. 23, p. 80, 1978.
Philippu et al., Chemical Abstract, vol. 99, No. 15, p. 137, 1983.
Ekas et al, Chemical Abstracts, vol. 98, No. 25, 210440t (1983).
Steppler et al., Chemical Abstracts, vol. 91: 16803M, 1979.
Steppler et al., Chemical Abstracts, vol. 90; 33949C, 1979.
Timmermans et al., Chemical Abstracts, 89:474V, 1978.
Boudier et al., Central and Perioneral alpha adrenergic activity of imidazoline derivatives, Chemical Abstracts, vol. 82, No. 17 p. 13 106180s (1975).
Burke et al., Current Eye Research, Sept. 5(9): 665-76, 1986.
Mittag, Annals of Ophthalmology, 15(3), 201-202, 1983.
Fielding, Medicinal Research Reviews, vol. 1, No. 1, pp. 97-123, 1981.
Isom et al., The Journal of Biological Chemistry, vol. 262, No. 14, pp. 6750-6757, May 1987.
Timmermans, Eur. J. Med. Chem., 15(4), pp. 323-329, (1980).
Nielsen et al, Br. J. Pharmacol, 97 (834), 1989.
Langer et al, Journal of Cardiovascular Pharm., vol. 7, Supp. 8 (S1-S8), 1985.
Sato et al, Science, vol. 251, pp. 1608-1610, Mar. 1991.
Gellai et al, The Journal of Pharmacology & Exp. Therap., 240(3), pp. 723-728, 1987.
Jarrot, Handbook of Hypertension, vol. 5, 113-168 (1984).
Bloor et al, Anesthesia & Analgesia, vol. 61, No. 9, 741-745, Sep. 1982.
Van Zwieten et al, Advances in Drug Research, vol. 13, 209-254, 1984.
Dharmsathaphorn, Gastroenterology, 91(3), 769-70, 1986.
Jumblatt et al, Current Eye Research, vol. 6, pp. 767-777, 1987.
Fondacaro et al, American Society for Phamacology, vol. 247, 1988, pp. 481-486.
Bendele et al, Pharmacol, 82, p. 152, Aug. 1991 (Abstract).
Hieble et al, The Pharmacol, 82, p. 152, Aug. 1991.
Goodman and Gilman et al, The Pharmacological Basis of Therapeutics, 7th ed. , Ch. 8, pp. 174-179, 1985.
Berridge et al, Br. J. Pharmac., 88(2), 345-354, 1986.
Gellai et al., Am. Physio. Soc., F317-323, 1988.
Colpaert, F. C. , Drug Development Research, 7:209-220, 1986.
Burke James A.
Garst Michael E.
Wheeler Larry A.
Allergan
Spivack Phyllis G.
Uxa Frank J.
LandOfFree
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivativ does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using (2-imidazolin-2-ylamino) quinoxaline derivativ, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using (2-imidazolin-2-ylamino) quinoxaline derivativ will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1859526